Alexis Thompson, MD, MPH, received the award at the society’s annual meeting.

Researchers found CAR T-cell therapy may serve as effective alternative for patients with these disorders.

CHOP researchers find exposing cells to a small molecule drug improves cell fitness during hematopoietic stem cell transplants, which could improve ex vivo gene therapy.

Leslie Raffini, MD, and Regina Butler, RN, were quoted in the Philadelphia Inquirer on a story featuring a CHOP patient family living with hemophilia, an inherited bleeding disorder that prevents blood from clotting properly.

CHOP and Penn researchers have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders directly within the body.

On a beautiful Saturday in June, Children’s Hospital of Philadelphia (CHOP) hosted the first in-person Cure Sickle Cell Walk & Family Fun Day at Citizens Bank Park raising more than $173,000 to support CHOP’s large and comprehensive sickle cell program.

CHOP researchers have identified a molecule that plays a role in post-translational modification and activation in myeloid cancers, making it a potential therapeutic target.

CHOP gene therapy expert Dr. Lindsey George reacts to a phase 3 hemophilia gene therapy study in an editorial in the New England Journal of Medicine.

CHOP experts in bleeding disorders care and research presented at the American Society of Hematology 2022 conference.

Nearly 50 faculty, staff and trainees from the Division of Hematology and Division of Oncology at Children’s Hospital of Philadelphia attended the 64th Annual American Hematology Society (ASH) Meeting in New Orleans, Louisiana.